

• **Name:**

LAURA PASQUALUCCI, M.D.

• **Current Position:**

Professor of Pathology & Cell Biology in the Institute for Cancer Genetics, Columbia University

• **Country:**

United States

• **Educational Background:**

|           |                                                                                                                                                                                              |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1991      | University of Perugia, School of Medicine<br>M.D., <i>Summa Cum Laude</i>                                                                                                                    |
| 1991-1995 | University of Perugia, School of Medicine<br>Residency in Hematology, <i>Summa Cum Laude</i>                                                                                                 |
| 1997-2001 | Postdoctoral Research Fellow<br>Molecular Genetics of Lymphoma (Dr. Riccardo Dalla-Favera)<br>Department of Pathology and Institute for Cancer Genetics<br>Columbia University, New York, NY |

• **Professional Experiences:**

|                  |                                                                                                                                    |
|------------------|------------------------------------------------------------------------------------------------------------------------------------|
| 12/2016-present  | Professor of Pathology & Cell Biology at CUMC (in the Institute for Cancer Genetics), Columbia University, New York, NY            |
| 4/2009-11/2016   | Associate Professor of Pathology & Cell Biology at CUMC (in the Institute for Cancer Genetics) Columbia University, New York, NY   |
| 10/2001-3/2009   | Assistant Professor of Clinical Pathology & Cell Biology (in the Institute for Cancer Genetics), Columbia University, New York, NY |
| 10/2007- present | Member, Herbert Irving Comprehensive Cancer Center, New                                                                            |

• **Professional Organizations**

**Memberships and Positions**

|              |                                     |
|--------------|-------------------------------------|
| 2022-present | Member, ICC                         |
| 2022-2023    | LRF LSRMP: Chair                    |
| 2016-2021    | ASH Committee on Scientific Affairs |

2020 ASH Meeting in Lymphoma Biology 2020: Co-Chair  
2014-present Member, American Association for Cancer Research  
2010-present Member, American Society of Hematology  
1993-2010 Member, Italian Society of Experimental Hematology

#### **Institutional Boards**

2023-present Institute of Follicular Lymphoma Innovation (IFLI): Moonshot Advisory Board  
2021 NCI Lymphoid Malignancies Branch: External Advisory Board  
2020-present LRF Jaime Peykoff Follicular Lymphoma Initiative: Committee  
2020-present Herbert Irving Comprehensive Cancer Center: Shared Resources Advisory Committee  
2019-2022 Leukemia and Lymphoma Society: TRP Grants Review Committee Chair  
2014-present Lymphoma Research Foundation: Grant Oversight Committee  
2013-present Lymphoma Research Foundation: Scientific Advisory Board  
2009-2013 Lymphoma Research Foundation: Board of Scientific Advisors

#### **Consultative (select list, past 10 years)**

2022-present European Research Council Evaluation Panel: Member  
2021-present ISSNAF Paola Campese Award: Reviewer  
2019-present Lymph&Co Foundation, the Netherlands: Grants Reviewer  
2019-present Florida Department of Health Biomedical Research Program: Grant Reviewer  
2019-present AACR and SU2C: Specific Advisory Committee  
2018-present NIH/NCI CAMP Study Section: Ad hoc Reviewer  
2018-present NIH/NCI Program Project (P01) Study Section: Ad hoc Reviewer  
2018-present Leukemia and Lymphoma Society, TRP Grants: Review Committee  
2018-present Nordic meeting on Tumor Microenvironment in Lymphoma: Abstracts Reviewer  
2016-present Medical Research Council UK: Grants Reviewer  
2015-present AACR Hematologic Malignancies Research Grants: Scientific Review Committee  
2015-present Leukemia and Lymphoma Society, CDP Grants: Review Committee  
2015-present Leukemia and Lymphoma Society, SCOR Grants: Review Committee  
2022 NCI Director's Pioneer Award: Reviewer  
2021 FWF Austrian Science Fund: Grant Reviewer  
2020 Swiss Cancer Research Foundation, Swiss Cancer league: Grants Reviewer  
2020 NIH/NCI MCT2 Study Section: Ad hoc Reviewer  
2020 Francis Crick Institute, UK: Grants Reviewer  
2019 Roche Late Stage Strategy Summit: Consultant  
2019 ASH Annual Meeting: Abstracts Reviewer - Lymphoma: Pre-Clinical  
2017 Kay Kendall Leukaemia Fund: Grants Reviewer  
2017 Juno Therapeutics, Advisory Board on DLBCL  
2017 ASH Annual Meeting: Abstract Reviewer - Lymphoma: Genetic/Epigenetic Biology  
2016 ASH Annual Meeting: Abstract Reviewer - Lymphoma: Genetic/Epigenetic Biology  
2016 ASH Meeting in Lymphoma Biology: Steering Committee  
2016 NIH Special Emphasis Panel ZRG1 F09A-D Fellowships Oncology, Mar3-4: Reviewer  
2016 NIH/NCI Cancer Genetics Study Section: Reviewer  
2016 ASH Meeting in Lymphoma Biology: Abstract Reviewer  
2015 NIH Special Emphasis Panel F09A-D Fellowships Oncology, July 20-21: Reviewer  
2015 Cancer Research UK: Reviewer  
2015 International Conference on Malignant Lymphoma Lugano: Abstracts Reviewer

|           |                                                                                  |
|-----------|----------------------------------------------------------------------------------|
| 2014-2015 | AACR Millennium Fellowships, Scientific Review Committee                         |
| 2014      | Leukemia and Lymphoma Research UK: Grants Reviewer                               |
| 2014      | NIH/NCI Developmental Therapeutics Study Section February 23-24: ad hoc Reviewer |
| 2014      | Ludwig Boltzmann Gesellschaft, Vienna, Austria: Grants Evaluation Committee      |
| 2014      | NIH/NCI Developmental Therapeutics Study Section June 19-20: ad hoc Reviewer     |
| 2014      | NIH/NCI Special Emphasis Panel Epidemiology of Cancer, March 7: hoc Reviewer     |
| 2013      | NIH/NCI Cancer Screening and Biomarker ZCA1RPRB-7(O1) S (R03, R21): Reviewer     |
| 2013      | Seitman Cancer Research Fund, Washington University in St Louis: Grants Reviewer |
| 2012      | NIH/NCI Special Emphasis Panels Training Grants (K01, K12): ad hoc Reviewer      |
| 2012      | NIH/NCI SPORE PROGRAM September 19-20: Peer Review Committee                     |
| 2012      | NIH/NCI SPORE PROGRAM February 8-9: Peer Review Committee                        |
| 2012      | Leukemia and Lymphoma Research UK: Grants Reviewer                               |

### Editorial Boards

|              |                                                                                           |
|--------------|-------------------------------------------------------------------------------------------|
| 2019-present | <i>Blood Cancer Discovery</i> , Board of Scientific Editors                               |
| 2017-present | <i>Journal of Experimental Medicine</i> , Advisory Editorial Board                        |
| 2009-2014    | <i>Blood</i> , Editorial Board                                                            |
| 2015         | <i>De Gruyter (pub)</i> , Malignant Lymphomas: Biology and Molecular Pathogenesis, Editor |

### Manuscript Reviewer

*Nature, Cell, Science, N Engl J Med, Nature Genetics, Nature Medicine, Nature Immunology, Nature Aging, Cancer Cell, Cancer Discovery, Blood Cancer Discovery, Nature Communications, Nature Cancer, Science Translational Medicine, Proc Natl Acad Sci USA, J Exp Med, Journal of Clinical Investigation, Blood, Cell Reports, Leukemia, Clinical Cancer Research, Cancer Research, Haematologica, Blood Advances, Br J Hematology, J Pathology, Frontiers in Immunology, Experimental Hematology*

### •Main Scientific Publications: (in reverse chronological order)

1. Vlasovska S, Garcia-Ibanez L, Duval R, Holmes AB, Jahan R, Cai B, Kim A, Mo T, Basso K, Soni RK, Bhagat G, Dalla-Favera R, **Pasqualucci L**. (2023). KMT2D acetylation by CREBBP reveals a cooperative functional interaction at enhancers in normal and malignant germinal center B cells. *Proc Natl Acad Sci USA*, 2023; 120(11):e2218330120. PMID: 36893259.
2. Bal E, Kumar R, Hadigol M, Holmes AB, Hilton LK, Loh JW, Dreval K, Wong JCH, Vlasovska S, Corinaldesi C, Soni RK, Basso K, Morin RD, Khiabani H, **Pasqualucci L**, Dalla-Favera R. Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. *Nature*, 2022; 607 (7920): 808-815. PMID: 35794478
3. Fangazio M, Ladewig E, Gomez K, Garcia-Ibanez L, Kumar R, Teruya-Feldstein J, Rossi D, Filip I, Pan-Hammarström Q, Inghirami G, Boldorini R, Ott G, Staiger AM, Chapuy B, Gaidano G, Bhagat G, Basso K, Rabadan R\*, **Pasqualucci L\***, Dalla-Favera R\*. Genetic mechanisms of HLA-

- I loss and immune escape in diffuse large B cell lymphoma. *Proc Natl Acad Sci U S A*, 2021; 118(22): PMID: 34050029. (\*equal contribution, corresponding authors)
4. Meyer SN, Scuoppo C, Vlassevka S, Bal E, Holmes AB, Holloman M, Garcia-Ibanez L, Nataraj S, Duval R, Vantrimont T, Basso K, Brooks N, Dalla-Favera R, **Pasqualucci L**. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. *Immunity*, 2019; 51(3):535-547. PMID:31519498.
  5. Zhang J, Vlassevka S, Wells VA, Nataraj S, Antony AB, Duval R, Meyer SN, Mo T, Basso K, Brindle PK, Hussein S, Dalla-Favera R, **Pasqualucci L**. The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B cell lymphoma. *Cancer Discovery*, 2017; 7(3): 322-337. doi: 10.1158/2159-8290. PMID: 28069569.
  6. Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, Vlassevka S, Mo T, Tang H, Basso K, Ge K, Dalla-Favera R, **Pasqualucci L**. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. *Nature Medicine* 2015; 21(10): 1190-1198.PMID: 26366712.
  7. **Pasqualucci L\***, Khiabani H, Fangazio M, Vasishtha M, Messina M, Holmes AB, Ouillet P, Trifonov V, Rossi D, Tabbò F, Ponzoni M, Chadburn A, Murty VV, Bhagat G, Gaidano G, Inghirami G, Malek SN, Rabadan R, Dalla-Favera R\*. Genetics of Follicular Lymphoma Transformation. *Cell Reports*, 2014; 6(1): 130-140. PMCID: PMC4100800. (\*corresponding Author)
  8. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R, Ciardullo C, Greco M, Cresta S, Piranda D, Holmes A, Fabbri G, Messina M, Rinaldi A, Wang J, Agostinelli C, Piccaluga PP, Lucioni M, Tabbò F, Serra R, Franceschetti S, Deambrogi C, Daniele G, Gattei V, Marasca R, Facchetti F, Arcaini L, Inghirami G, Bertoni F, Pileri SA, Deaglio S, Foà R, Dalla-Favera R\*, **Pasqualucci L\***, Rabadan R\*, Gaidano G\*. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. *J Exp Med*, 2012; 209(9): 1537-51. (\*corresponding authors)
  9. **Pasqualucci L\***, Dominguez-Sola D, Chiarenza A, Fabbri A, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK and Dalla-Favera R\*. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature*, 2011; 471(7337):189-195. PMID: 21390126; PMCID: PMC3271441. (\*corresponding authors)
  10. Challa-Malladi M, Lieu YK, Califano O, Holmes A, Bhagat G, Murty VV, Dominguez-Sola D, **Pasqualucci L\***, Dalla-Favera R\*. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. *Cancer Cell*, 2011; 20(6): 728-740. (\*equal contribution)
  11. **Pasqualucci L\***, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O, Chan J, Bhagat G, Chadburn A, Gaidano G, Mullighan CG, Rabadan R, Dalla-Favera R\*. Analysis of the coding genome of diffuse large B cell lymphoma. *Nature Genetics*, 2011; 43:830-837, 2011. PMID: 21804550; PMCID: PMC3297422. (\*corresponding authors)
  12. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabani H, Ma J, Grunn A, Fangazio M, Capello D, Monti S, Cresta S, Gargiulo E, Forconi F, Guarini A, Arcaini L, Paulli M, Laurenti L, Larocca LM, Marasca R, Gattei V, Oscieri D, Bertoni F, Mullighan CG, Foa' R, **Pasqualucci L\***, Rabadan R\*, Dalla-Favera R\*, Gaidano G\*. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. *J Exp Med*, 2011; 208(7):1389-1401. (\*equal contribution)

13. Mandelbaum J, Bhagat G, Tang H, Mo T, Grunn A, Brahmachary M, Shen Q, Chadburn A, Rajewsky K, Tarakhovsky A, **Pasqualucci L\***, Dalla-Favera R\*. Blimp1 is a tumor suppressor gene frequently disrupted in activated B-cell like diffuse large B cell lymphoma. *Cancer Cell*, 2010; 18(6):568-579. (\*equal contribution)
14. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Berton F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, **Pasqualucci L**. Mutations in multiple genes cause deregulation of the NF- $\kappa$ B pathway in diffuse large B-cell lymphoma. *Nature*, 2009; 459(7247):717-721. PMID: 19412164; PMCID: PMC2973325
15. **Pasqualucci L\***, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, Honjo T, Morse HC 3rd, Nussenzweig MC, Dalla-Favera R\*. AID is required for germinal center-derived lymphomagenesis. *Nature Genetics*, 2008; 40:108-112. (\*corresponding authors).
16. **Pasqualucci L\***, Kitauro Y, Gu H, Dalla-Favera R. PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. *Proc Natl Acad Sci USA*, 2006; 103: 395-400. (\*corresponding author)
17. Cattoretti G\*, **Pasqualucci L\***, Ballon G, Tam W, Nandula SN, Shen Q, Mo T, Murty VV, Dalla-Favera R. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B-cell lymphomas in mice. *Cancer Cell*, 2005; 7:445-455. (\*equal contribution)
18. **Pasqualucci L**, Migliazza A, Basso K, Houldsworth J, Chaganti RS, Dalla-Favera R. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood*, 2003; 101(8): 2914-2923.
19. **Pasqualucci L**, Neumeister P, Goossens T, Nanjangud G, Chaganti RSK, Küppers R, Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell Diffuse Large Cell Lymphomas *Nature*, 2001; 412: 341-346.
20. **Pasqualucci L**, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti RSK, Klein U, Küppers R, Rajewsky K, Dalla-Favera R. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. *Proc Natl Acad Sci USA*, 1998; 95 (20): 11816-11821.